Search News Archives
Follow us on
Conferences | Events

Media Partners

 

Cancer Relapse Linked to Body’s Own Immune System

publication date: Nov 2, 2017
 | 
author/source: The Institute of Cancer Research

Cancer cells use immune response to boost their growth - Immunotherapy could get body’s response back on track - Early data suggests existing immunotherapies could prevent relapse

ICRCancer cells that survive after treatment may use the body’s own immune system to wake themselves up and fuel their growth, a new study shows.

The research sheds new light on how the immune system loses its ability to keep cancer in check, leading to the patient relapsing.

And the researchers found immunotherapy could be effective at preventing relapse, by getting the body’s immune response back on track.

Scientists at The Institute of Cancer Research, London, with colleagues in Leeds, Surrey and the US, aimed to understand how a small number of cancer cells that resist treatment can turn deadly after lying dormant for long periods.

The researchers studied the immune response in mice to investigate how the cells of the immune system behaved before initial treatment, after treatment appeared to have worked, and when tumours returned.

The study is published today (Monday) in the journal Cancer Immunology Research and was funded by the European Research Council, the Richard M Schulze Family Foundation, the Mayo Foundation, Cancer Research UK, and the US National Institutes of Health.

Immune cells normally release signals that trigger inflammation in response to trauma or infection which, in some circumstances, can help the immune system kill cancer cells.

But the new research suggests these signals are subverted by leftover cancer cells after treatment, and used to drive their aggressive growth during relapse.

Crucially, the researchers showed that immunotherapies that target this response could either delay or prevent cancer returning in mice – suggesting that this approach could be effective in patients at risk of relapse.

Researchers found that a chemical signal called TNF-alpha switches in its effect from an anti-tumour agent that supports the immune response to eliminate cancer cells, to a new type of signal that promotes cancer relapse.

Resistant cells were also able to tell immune cells called natural killer cells to turn a blind eye, so that the relapsing cancer cells could grow unchecked.

Researchers found that the resistant cancer cells had high levels of a molecule called PD-L1 on their surface, which interacts with PD-1 on immune cells called T cells to tell them not to attack.

PD-1 is the target for highly successful immune checkpoint inhibitor drugs, and the researchers showed these treatments could delay or prevent relapse in mice.

Study co-author Professor Alan Melcher, Professor of Translational Immunotherapy at The Institute of Cancer Research, London, said:

“Our study finds the body’s own immune system seems to play a crucial role when cancer relapses. The immune system goes from keeping cancer cells in check to awakening and feeding residual cells, while turning a blind eye to their growth.

“Excitingly, many of the methods employed by treatment-resistant tumours to re-grow and hide from the immune system can be blocked using existing immunotherapies. This idea is, in fact, supported by emerging data from clinical trials, showing that immunotherapies can reduce the risk of cancers coming back.”

Study co-author Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, said:

“It is becoming increasing clear that the immune system is at the core of the puzzle of how we can treat cancer more effectively.

“This fascinating new study helps explain why sometimes a patient’s immune system can be effective against cancer cells while at other times it is not. It also shows there is a lot more to learn about the nature of those cancer cells that lie dormant as a way of resisting the killing effects of cancer treatments. Changes must occur in these cells that make them better able to manipulate the immune system – and understanding this could open up new treatment options to prevent relapse.”


more about ICR


 



 

Popular this month

 

Thermo Fisher Scientific’s Analytical Instruments Receive Industry Recognition with Prestigious Awards


Bruker Introduces new SKYSCAN 1273 Benchtop 3D X-ray Microscope


How To Increase Productivity & Efficiency In Laboratories


Opportunities and challenges in the booming North American cannabis market


ZEISS Develops First Multifunctional Smart Glass


Eppendorf & Science Prize for Neurobiology 2019: Call for Entries!


Industry forecast for analytical instruments market in 2019


MGI Introduces Automated Sample Preparation Workstations, Streamlining Genomic Sequencing Workflow


WIN a VIAFLO 96/384 to supercharge your microplate pipetting!


Know the Unknown – with Cora Raman Spectrometers from Anton Paar

 


 

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd